{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Virax Biolabs Group Limited"},"Symbol":{"label":"Symbol","value":"VRAX"},"Address":{"label":"Address","value":"30 BROADWICK STREET, LONDON, W1F 8JB, United Kingdom"},"Phone":{"label":"Phone","value":"+44 2077887414"},"Industry":{"label":"Industry","value":"Biotechnology: In Vitro & In Vivo Diagnostic Substances"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases with a particular interest in the field of immunology. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus."},"CompanyUrl":{"label":"Company Url","value":"https://www.viraxbiolabs.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"James Foster","title":"Chairman & Chief Executive Officer"},{"name":"Nigel McCracken","title":"Chief Operating Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}